

# delafloxacin 300mg powder for concentrate for solution for infusion and 450mg tablets (Quofenix®)

A. Menarini Farmaceutica Internazionale SRL

4 June 2021

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation **delafloxacin (Quofenix®)** is not recommended for use within NHSScotland.

**Indication under review:** treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

## Advice context:

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

**Chairman  
Scottish Medicines Consortium**